The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Chuguev A.S.

National Research Medical Center of Radiology

Gerasimov V.A.

National Research Medical Center of Radiology

Belikova A.A.

National Research Medical Center of Radiology

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia;
Peoples’ Friendship University of Russia

Datsenko P.V.

National Research Medical Center of Radiology

The choice of radiotherapy dose fractionation regimen for grade 4 gliomas depending on the status of MGMT

Authors:

Chuguev A.S., Gerasimov V.A., Belikova A.A., Kaprin A.D., Datsenko P.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(1): 13‑18

Views: 347

Downloaded: 0


To cite this article:

Chuguev AS, Gerasimov VA, Belikova AA, Kaprin AD, Datsenko PV. The choice of radiotherapy dose fractionation regimen for grade 4 gliomas depending on the status of MGMT. P.A. Herzen Journal of Oncology. 2025;14(1):13‑18. (In Russ.)
https://doi.org/10.17116/onkolog20251401113

Recommended articles:
Early chemotherapy between surgery and radiotherapy in grade 4 gliomas. P.A. Herzen Journal of Onco­logy. 2024;(5):12-17
Patients with long-term survival in mali­gnant gliomas after photodynamic therapy. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(6):54-61
The Russian consensus on the treatment of intrahepatic cholangiocarcinoma. Piro­gov Russian Journal of Surgery. 2024;(10):7-20

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.